Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
131I-omburtamab for neuroblastoma with central nervous system or leptomeningeal metastasis in paediatric patients	Omburtamab I-131 (131I-mu8H9)	Neuroblastoma	Neurological Cancer	2019	View \| Download
Acalabrutinib for chronic lymphocytic leukaemia – first line	Acalabrutinib (Calquence; ACP-196)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2019	View \| Download
Acalabrutinib for relapsed/refractory Chronic lymphocytic leukaemia	Acalabrutinib (Calquence; ACP-196)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2019	View \| Download
Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer	Adstiladrin (Nadofaragene firadenovec; rAd-IFN/Syn3; Instiladrin)	Bladder cancer	Urological Cancer	2019	View \| Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Bladder cancer	Urological Cancer	2019	View \| Download
Atezolizumab for stage IV non-squamous or squamous non-small cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Atezolizumab in addition to cobimetinib and vemurafenib for BRAF mutated metastatic melanoma	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) , Vemurafenib (Zelboraf; PLX4032; R7204; RO5185426; PLX-4032; RG7204)	Melanoma	Skin Cancer	2019	View \| Download
Atezolizumab in addition to paclitaxel for inoperable, locally advanced or metastatic triple negative breast cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Paclitaxel (Taxol; paclitaxel albumin)	Breast cancer	Breast Cancer	2019	View \| Download
Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Atezolizumab in combination with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download